Results 231 to 240 of about 1,254,591 (276)

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon   +14 more
wiley   +1 more source

Longitudinal Metabolic Risk Factors Are Associated With Microvascular Complications

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Determine associations between summaries of longitudinal metabolic risk factors and microvascular complications. Methods We performed a secondary analysis of participants with and without diabetes enrolled within the Atherosclerosis Risk in Communities Study that completed metabolic risk factors assessments four times across 11 years.
Cody H. Makinson   +4 more
wiley   +1 more source

Excitatory paraventricular thalamus-posterior insular cortex circuit mediates pain-anxiety comorbidity in diabetic neuropathy. [PDF]

open access: yesTransl Psychiatry
Wei M   +16 more
europepmc   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre   +6 more
wiley   +1 more source

Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang   +6 more
wiley   +1 more source

Integrating gut microbiota into multidisciplinary perspectives on diabetic neuropathy. [PDF]

open access: yesFront Endocrinol (Lausanne)
Horiachok M   +5 more
europepmc   +1 more source

Prevalence of Chronic Complications After Inaugural Admission in Intensive Care Unit for Type 1 Diabetes in the SFDT1 Cohort: The INAUGURAL Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Inaugural presentation at type 1 diabetes onset, as ketoacidosis, has been associated with poorer glycaemic control, but its relationship to diabetes‐related complications remains unclear. We assessed the association between inaugural intensive care unit (ICU) admission and long‐term diabetes‐related outcomes in adults.
Emmanuel Cosson   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy